Are Combinations the Answer in Metastatic RCC?

home / investigator-perspectives / are-combinations-the-answer-in-metastatic-rcc

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.

EP. 1: Historic Level of Progress in First-Line RCC Treatment

Targeted Oncology

March 29th 2021

An expert in genitourinary oncology, Robert J. Motzer, MD, reviews the recent historic advances in frontline combinations for the treatment of advanced clear-cell renal cell carcinoma.

Watch

EP. 2: Strong Efficacy and Favorable Safety From CLEAR for RCC

Targeted Oncology

March 29th 2021

A comprehensive review of the efficacy and safety data from the phase 3 CLEAR trial (Study 307/KEYNOTE-581) for the frontline treatment of advanced renal cell carcinoma.

Watch

EP. 3: Dosing Strategies to Maximize Efficacy in RCC

Targeted Oncology

March 29th 2021

Robert J. Motzer, MD, discusses dosing strategies to mediate toxicities and maximize efficacy from the frontline combination of lenvatinib plus pembrolizumab for renal cell carcinoma.

Watch

EP. 4: Considerations for Len-Pembro in Clinical Practice

Targeted Oncology

March 29th 2021

Expert perspectives on the clinical utility of lenvatinib plus pembrolizumab as a frontline combination for advanced renal cell carcinoma.

Watch

EP. 5: What’s Next for Advanced RCC?

Targeted Oncology

March 29th 2021

A look toward the future treatment of advanced renal cell carcinoma.

Watch

About Us